

CORPORATE PROFILE

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies and the company generates more than \$5 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

STOCK PERFORMANCE

BIIB (COMMON STOCK)

Exchange NASDAQ (US Dollar)
 Price **\$280.32**
 Change (%) ▼ 0.25 (0.09%)
 Volume 2,439,562
 52 Week Low \$205.43
 Market Cap \$59,880,915,049
 Rolling EPS 15.96
 PE Ratio 17.5639
 Shares Outstanding 213,616,278
 Data as of 06/23/17 4:00 p.m. ET



RECENT PRESS RELEASES

- 06/23/17
Biogen's IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use
- 06/20/17
Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer
- 06/14/17
Jean-Paul Kress Appointed EVP and President, International and Head of Global Therapeutic Operations
- 06/13/17
Biogen Announces Management Change
- 06/01/17
SPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy

UPCOMING EVENTS

There are currently no events scheduled.

RECENT SEC FILINGS

FILING DATE	FORM
06/20/17	3
06/16/17	S-8
06/13/17	8-K
06/12/17	4
06/09/17	4

ANALYST ESTIMATES / RATINGS

Mean Recommendation: 2.1



Sell

Strong Buy

EPS TREND

		Current	30 Days Ago	90 Days Ago
QTR	Jun 17	4.52	4.54	5.22
QTR	Sep 17	5.35	5.35	5.33
QTR	Dec 17	5.40	5.40	5.43
QTR	Mar 18	5.34	5.34	5.32
FY	Dec 17	20.47	20.48	20.96
FY	Dec 18	22.50	22.57	22.38

OWNERSHIP SUMMARY

	Holders	Value (\$MM)	% O/S	Shares
Institution	1,461	52,792.63	91.0	192,966,859
Mutual Fund	2,587	30,288.04	52.8	111,980,439
Insider *	22	77.66	0.1	300,710

**Insider values reflect direct beneficial ownership.*

	Shares Held	% O/S	Share Change	Filing Date
PRIMECAP Management Company	15,477,424	7.3	-106,963	03/31/17
The Vanguard Group, Inc.	14,352,490	6.8	342,568	03/31/17
BlackRock Institutional Trust Company, N.A.	11,705,223	5.5	304,532	03/31/17
State Street Global Advisors (US)	9,580,383	4.5	219,502	03/31/17
ClearBridge Investments, LLC	9,121,025	4.3	351,224	03/31/17
T. Rowe Price Associates, Inc.	8,118,191	3.8	-600,042	03/31/17
Wellington Management Company, LLP	5,712,355	2.7	-131,919	03/31/17
Fidelity Management & Research Company	5,393,494	2.5	-2,442,595	03/31/17
AllianceBernstein L.P.	2,937,319	1.4	294,308	03/31/17
Sands Capital Management, LLC	2,475,937	1.2	-102,972	03/31/17

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed